Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Németország1. fázis

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

A legfontosabb adatok

Ki végzi
Technische Universität Dresden
Hol
Dresden (Németország)A helyszín megnézése
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
16 fő, tervezett
Kezdés
2024. febr. 15.
Várható befejezés
2027. jún.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
A regiszteradat frissítve
2026. augusztus 27.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek a myeloma multiplexe vagy a diffúz nagy B-sejtes limfómája kiújult, vagy nem reagált a kezelésre. A BCMA-ra irányuló CAR T-sejtek biztonságosságát vizsgálják.

Életkor
18 éves vagy idősebb
Nem
Férfiak és nők
A betegség stádiuma
Myeloma multiplex, amely legalább 2 kezelési vonal után kiújult vagy nem reagált a kezelésre, vagy diffúz nagy B-sejtes limfóma, amely a standard kezelésre kiújult vagy nem reagált. A betegségnek mérhetőnek kell lennie, és nem lehet más, bizonyítottan hatásos standard kezelés.
Korábbi kezelés
Myeloma esetén: immunmoduláns szer, proteaszóma-gátló és anti-CD38 vagy anti-CD319 (SLAMF7, elotuzumab) ellenanyag. Limfóma esetén: standard kezelés, például R-CHOP, és mentő kemoterápia, vagy kiújulás őssejt-átültetés vagy engedélyezett anti-CD19 CAR T-sejtes kezelés után.

A részvétel fő kizáró okai

  • A központi idegrendszer érintettsége
  • Hemodialízis
  • HIV-ellenanyag-pozitivitás, vagy aktív vagy krónikus B- vagy C-hepatitis
  • Aktív graft versus host betegség
  • Terhes vagy szoptató nők

A regiszter feltételei, szó szerint

Mind a 33 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female patients aged ≥ 18 years
  • Written informed consent of the subject
  • Able and willing to adhere to the trial protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Either Multiple Myeloma (MM):; relapsed or refractory disease after at least 2 lines of treatment including an Immunomodulatory drug, a proteasome inhibitor and an anti-cluster of differentiation 38 antibody or anti-cluster of differentiation 319 (SLAMF7; Elotuzumab) antibody AND; not eligible for treatment with other regimen available according to local standard of care and known to confer clinical benefit according to the investigator's discretion, prior treatment with other BCMA-targeting immunotherapies (including T-cell engaging antibodies, CAR T-cells and antibody-drug immuno-conjugates) is allowed AND; measurable disease defined by serum M-Protein ≥ 10 g/l OR urine M-Protein ≥ 200 mg/24h OR serum free light chain > 100 mg/l of involved free light chain and abnormal serum free light chain ratio; OR; Diffuse large B-cell lymphoma (DLBCL):; Relapsed after or refractory to standard curative therapy (such as R-CHOP) and refractory to at least one course of standard salvage chemotherapy OR; Relapsed within one year after high-dose chemotherapy and autologous stem cell support OR; Relapsed after allogeneic stem-cell transplantation or approved anti-cluster of differentiation 19 CAR T-cell therapies; AND (applicable to all DLBCL patients); Not be eligible for treatment with other regimen available according to local standard of care and known to confer clinical benefit. This includes but is not limited to anti-cluster of differentiation 19 directed CAR T-cell therapies with approved constructs AND (applicable to all DLBCL patients); Measurable disease according to Lugano criteria
  • Adequate organ function defined as:; Neutrophils ≥ 0.5 Gpt/l and Platelets ≥ 50 Gpt/l (unless due to subtotal infiltration of the bone marrow by underlying malignancy); Lymphocytes ≥ 0.1 Gpt/l; Alaninaminotransferase and Asparataminotransferase ≤ 3.0x Upper limit of normal; Bilirubin ≤ 1.5x Upper limit of normal; Creatinine ≤ 1.5x Upper limit of normal; Adequate cardiac function i.e. left ventricular ejection fraction ≥ 50%, no major valve abnormalities or dyskinesias
  • A female of childbearing potential* may be enrolled providing she has a negative pregnancy test at screening and is routinely using a highly effective method of birth control (pearl index of ≤ 1 required) resulting in a low failure rate (e.g. hormonal contraception, intrauterine device, total sexual abstinence or sterilization). Male patients must also prac-tice a highly effective method of birth control and should not father a child at least until 12 months after infusion of CAR T-cells

Ki nem vehet részt

  • Active Graft versus Host Disease defined as active symptoms of graft-versus-host disease or ongoing immunosuppressive treatment or prophylaxis within the last 30 days prior to application of MDC-CAR-BCMA001
  • Patients who are expected to deteriorate during the time needed for manufacturing MDC-CAR-BCMA001 in spite of bridging therapy in the opinion of the investigator including
  • Any condition requiring systemic treatment with immunosuppressive drugs (including but not limited to steroids exceeding 20 mg Prednisolone per day)
  • Any antineoplastic treatment within 7 days prior to leukapheresis or within 2 weeks or 5 half-lives (whatever is shorter) of the start of lymphodepleting chemotherapy (palliative radiotherapy to lesions not essential for response assessment is allowed without a minimal washout period)
  • Any investigational therapy within 4 weeks or 5 half-lives (whatever is shorter) prior to apheresis or the start of lymphodepleting chemotherapy
  • Receipt of live vaccines within 2 weeks prior to leukapheresis and start of lymphodepleting chemotherapy
  • Simultaneous participation in another interventional clinical trial (including within the last 4 weeks before inclusion)
  • Any Central nervous system (CNS)-involvement by underlying disease
  • History of seizure or cerebrovascular ischemia / hemorrhage within the last 12 months
  • History of any autoimmune Central nervous system disease (e.g. multiple sclerosis, amyotrophic lateral sclerosis, optic neuritis)
  • Ongoing neurologic conditions that in the opinion of the investigator might increase the risk for neurotoxicity or impair the assessment of CAR-associated neurotoxicity
  • Any other active malignancy requiring active treatment or interfering with the assessment of primary or secondary trial endpoints, adjuvant hormonal therapy is allowed
  • Positivity for anti-human immunodeficiency virus (HIV) immunoglobulin
  • Active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) or history of SARS-CoV2 infection within the past 3 months or active long coronavirus disease (COVID) syndrome
  • Uncontrolled bacterial, viral or fungal infections defined as infections needing in-patient and/or i.v. antimicrobial treatment*
  • Psychologic disorders, drug abuse or any other condition which might significantly impair a patient's ability to comply with the trial protocol
  • History of allergic reactions to any drug or its ingredients / impurities foreseen to be given as part of this trial according to the protocol*
  • Hypersensitivity known from medical history to one of the drugs used or their ingredients or to drugs with a similar chemical structure
  • Addictions or other illnesses that do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences
  • Active or chronic infectious hepatitis B (HBV) and C (HCV) virus unless serology demonstrates clearance of infection (i.e. Polymerase chain reaction undetectable viral load for hepatitis)
  • Women of childbearing potential, except women who meet the following criteria:; post-menopausal (12 months natural amenorrhoea or 6 months amenorrhoea with serum Follicle stimulating hormone > 40 U/ml); postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy); regular and correct use of a contraceptive method with an Pearl Index < 1% per year; sexual abstinence; Vasectomy of the partner
  • Inadequate pulmonary function (i.e. need for continuous oxygen support)
  • Patients on hemodialysis
  • Any contraindications to Fludarabine and/or Cyclophosphamide as given in the Summary of product characteristics
  • Pregnant or breastfeeding women. Breastfeeding has to be discontinued before onset of and during treatment and should be discontinued for at least 3 months after end of treatment
  • Indications that the subject is unlikely to adhere to the protocol (e.g., lack of compliance)

Ez a vizsgálat jelenleg itt érhető el: Németország.

  • Technische Universität DresdenDresden, NémetországRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies

A vizsgálat csoportja

  • MDC-CAR-BCMA001A vizsgált kezelés

    MDC-CAR-BCMA001 will be administered intravenously in ascending dose levels. This trial will test a total of 4 dose levels in order to identify the MTD and/or recommended phase 2 dose for MDC-CAR-BCMA001.

    Kezelés: MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell Malignancies
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2026. augusztus 27.